Cardio/Pulmonary

Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
Dr. John Cush @RheumNow( View Tweet )
EULAR.Docs.APP

Day 4 EULAR Report

Jack Cush, MD

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and

Read Article
ILD.colors

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest

Jiha Lee, MD

At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool

Read Article
Depression at RA diagnosis did not predict short-term CV events in a nationwide early RA cohort -17,669 early RA pts -7.3% BL depression -Median follow-up 1.2 years -No association w/ CV hospitalisation after adjustment (sHR 1.05) Reassuring short-term data, longer follow-up https://t.co/XmMVGY1VlI

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
How to treat #RA-#ILD Similar to #IPF Occurs older men esp Smoking risk Vaccines Etc Philippe Dieude #HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF

Links:

Janet Pope @Janetbirdope( View Tweet )
Hypertension was the most robust and consistent predictor of pre term labor. Data from germany nationwide #POS1062 @RheumNow ##EULAR2026 https://t.co/Uccf11PpAK

Links:

Bella Mehta @bella_mehta( View Tweet )
holding hands together support frail

New biomarkers in RA: Who to treat, Who to watch, Who to taper?

Aurelie Najm, MD, PhD

Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.

Read Article
#OP0350 UK Biobank analysis found widespread white matter microstructural abnormalities on diffusion MRI in RA, esp in fronto-subcortical & transcallosal pathways, despite no cortical volume/thickness differences on T1 MRI. #EULAR2026 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

Lung.Pleural.inflamm.AI

RA-ILD: Screening risk and genetic susceptibility

Mrinalini Dey, MD

RA-ILD remains one of the most serious extra-articular manifestations of RA, contributing substantially to morbidity and mortality. Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin

Read Article
Who should we screen for RA-ILD? RA-ILD remains a serious extra-articular manifestation, contributing to morbidity and mortality. At #EULAR2026, two abstracts shed light on clinical phenotyping and risk profiling. Read my report for @RheumNow: https://t.co/CTtYHINXxU

Links:

Mrinalini Dey @DrMiniDey( View Tweet )

Catching your breath session at #EULAR2026 RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr) Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks) @RheumNow https://t.co/V1JXM3i9wP

Links:

Jiha Lee @JihaRheum( View Tweet )
EULAR flags

Understanding Comorbidities in RMD

2026 EULAR Press Release

People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD –

Read Article
#OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

#OP088 at #EULAR2026 found that rare deleterious variants in telomere-related genes were associated with increased RA-ILD risk, independent of MUC5B status. The effect size was similar to that seen in idiopathic pulmonary fibrosis. @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

#Autoimmune #progressive #pulmonary #fibrosis Large Spanish registry ❎more mortality if not on #DMARDs ?underRx of proven #Rx with #antifibrotics Median survival post #dx #PPF 7.8 yrs Can we do better? #ABST POS0430 @RheumNow #EULAR2026 https://t.co/gP7apxfEPS

Links:

Janet Pope @Janetbirdope( View Tweet )
Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084 ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

Does #Rx w #immunesuppression w #antifibrotic Help #SARD-ILD? YES. N=40 SARD-ILD, 1/2 w UIP pattern Use of #IS w #antifibrotic pt group had better survival Small N and ?channeling bias But interesting results TAke home : Use IS + antifibrotic #EULAR2026 #POS0530 @RheumNow https://t.co/tfxVVw27jJ

Links:

Janet Pope @Janetbirdope( View Tweet )
RA comorbidities are changing. ILD, anxiety, depression increasing. Less extraartic. manifestations, CA & CV dz. Consider screening for cervical CA, ILD, CV dz & OP (for pts on steroids) https://t.co/WVITFXNva7 https://t.co/tggdaO9RJB

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
Hopkins study of HCQ in discoid lupus (DLE) - 5 yr outcomes of 106 adult DLE; those on HCQ had less hyperlipidemia (HL), PAD, angina, & CAD. Parallel TriNetX study showed HCQ assoc w/ signif less HTN, HL, DM, CAD, & CVA. https://t.co/yX7FkGCnvR https://t.co/oddq68FYeE

Links:

Dr. John Cush @RheumNow( View Tweet )
10yr retrosp. study of 110 Still’s dz pts. MAS occurred in 37% (1/2 @onset; assoc w/ serositis) and ILD observed in 82% (also assoc w/ MAS, polycyclic course) https://t.co/SNa0KiWfgY https://t.co/xbpCuHdJka

Links:

Dr. John Cush @RheumNow( View Tweet )
RA adds to mortality risk in nontuberculous mycobact. infx (NTM). Retro study 1420 NTM pts, 66 (4.6) had RA. RA was independent predictor of resp-death (HR 4.30) - partly explained by ILD & systemic inflammation https://t.co/S9bndHsXCE https://t.co/mC74Qve1LZ

Links:

Dr. John Cush @RheumNow( View Tweet )
Eosinophil

EGPA Review

Jack Cush, MD

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

Read Article
Predictors of renal crisis & pulm. arterial HTN (PAH) in systemic sclerosis - retrospect. study of 234 SSc pts; 7.3% had PAH & SRC. PAH may precede overlap w/ SRC. SSc w/ both at hi risk for GI bleed (OR 9.5). SRC+PAH assoc w/ Older age, elevated NT-proBNP https://t.co/MsaiPdcDrb https://t.co/CyMrL8izxP

Links:

Dr. John Cush @RheumNow( View Tweet )

Therapeutic Updates

ILD Treatment and Guidelines

Hinze title card
Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more.
Read Post

Recent Blogs

rheumthought

Overlap Syndrome with ILD

Jack Cush, MD
Cush RheumThought ILD

How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?

Read Article

Best of 2023: New ACR RA-ILD Treatment Guidelines – What Were They Smoking!?

Richard Conway, MBBChBAO, PhD
Lungs ILD
Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients. There is a very limited evidence base supporting treatment and therefore the recent release of ACR guidelines is to be welcomed. However, the published guidelines appear discordant with the best available evidence base. 
Read Post
rheumthought

Screening and Overdiagnosis of ILD in RA

Michael Putman, MD, MSCI
Putman RheumThoughts
Dr. Michael Putman (Milwaukee, WI) reviews his approach to screening for ILD and RA, the potential for overdiagnosis and how this impacts treatment choices. Does this differ from your approach?
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR Podcast - Day1A
  • EULAR 2021 - Day2c 00:37:25
×